


Les données nationales de la prise en charge des amyloses cardiaques

LES DONNÉES EN VIE RÉELLE DES TRAITEMENTS

Olivier LAIREZ
CHU de Toulouse





Les données nationales de la prise en charge des amyloses cardiaques

LES DONNÉES *EN VIE RÉELLE* DES TRAITEMENTS


Olivier LAIREZ


CHU de Toulouse





Amylose cardiaque à transthyrétine







Stabilisateurs


Tafamidis


Stabilisateur du tétramère





Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy





Clinical outcomes for 2788 transthyretin amyloidosis patients: tafamidis meglumine early access program in France

Characteristics and clinical outcomes of *ATTR*-CM patients initiated with tafamidis meglumine in the French early access program from Nov 2018 to Jun 2021

2788 *ATTR*-CM patients were enrolled
by 222 physicians from 126 centers

	Total number of centres (N=126)	Total number of patients (N=2788)
--	------------------------------------	--------------------------------------

Patients included / centre

≥ 200 patients	2* (1.6%)	821 (29.4%)
100-199 patients	2** (1.6%)	269 (9.6%)
50-99 patients	10 (7.9%)	718 (25.8%)
10-49 patients	32 (25.4%)	749 (26.9%)
< 10 patients	80 (63.5%)	231 (8.3%)




82 years
82% male

NYHA

- stage I 13%
- stage II 60%
- stage III 27%


*ATTR*v 18%

Demographic and Clinical Characteristics of the Patients at Baseline.*		
Characteristic	Tafamidis (N=264)	Placebo (N=177)
Age — yr		
Mean	74.5±7.2	74.1±6.7
Median (range)	75 (46–88)	74 (51–89)
Sex — no. (%)		
Male	241 (91.3)	157 (88.7)
Female	23 (8.7)	20 (11.3)
NYHA Class — no. (%)		
Class I	24 (9.1)	13 (7.3)
Class II	162 (61.4)	101 (57.1)
Class III	78 (29.5)	63 (35.6)
TTR genotype — no. (%)		
<i>ATTR</i> m	63 (23.9)	43 (24.3)
<i>ATTR</i> wt	201 (76.1)	134 (75.7)



Clinical outcomes for 2788 transthyretin amyloidosis patients: tafamidis meglumine early access program in France


Number of patients
included in tafamidis RTU





82 years
82% male


NYHA
- stage I 13%
- stage II 60%
- stage III 27%

ATTRv 18%






Clinical outcomes for 2788 transthyretin amyloidosis patients: tafamidis meglumine early access program in France





Clinical outcomes for 2788 transthyretin amyloidosis patients: tafamidis meglumine early access program in France







Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide and High-Sensitivity Troponin T Levels in the Natural History of Transthyretin Amyloid Cardiomyopathy and Their Evolution after Tafamidis Treatment

NT-proBNP



Cohort A, Before Tafamidis




Cohort B, Under Tafamidis





cTnT-HS






Effect of tafamidis on global longitudinal strain and myocardial work in transthyretin cardiac amyloidosis








Effect of Tafamidis on Cardiac Function in Patients With Transthyretin Amyloid Cardiomyopathy


A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial







Tafamidis Decreases Cardiac Uptake of ^{99m}Tc -HMDP in Transthyretin Cardiac Amyloidosis






Oligonucléotides






Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis


□ Change from Baseline in 6-Minute Walk Test






Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis


Change from Baseline in Kansas City Cardiomyopathy Questionnaire—Overall Summary






Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis


Change from Baseline in NT-proBNP Level





Patisiran treatment for ATTR cardiac amyloidosis: 18-Month Results of the Phase 3 APOLLO-B Study


Mean Change from Baseline in 6-MWT



No. of patients

Placebo	178	165	165	164	146
Patisiran	181	162	167	167	149


Mean Change from Baseline in KCCQ-OS



No. of patients


Placebo	178	171	168	167	155
Patisiran	181	170	171	171	157

■ Patisiran ■ Placebo



Patisiran treatment for ATTR cardiac amyloidosis: 18-Month Results of the Phase 3 APOLLO-B Study


**Geometric Mean Fold Change from
Baseline in NT-proBNP**



No. of patients
Placebo
Patisiran

Baseline	3	6	9	12	15	18
178	168	165	164	163	156	152
181	171	169	169	167	157	157

**Geometric Mean Fold Change from
Baseline in Troponin I**



No. of patients
Placebo
Patisiran


Baseline	3	6	9	12	15	18
172	158	162	156	155	150	145
174	161	162	160	158	146	147




Patisiran




Placebo



Reduction in CMR Derived Extracellular Volume with Patisiran Indicates Cardiac Amyloid Regression





Amylose cardiaque à transthyrétine

